Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 21;50(SI-1):611-619.
doi: 10.3906/sag-2004-145.

Antiviral treatment of COVID-19

Affiliations
Review

Antiviral treatment of COVID-19

Serap Şimşek Yavuz et al. Turk J Med Sci. .

Abstract

Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%–10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be published in the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other human infections.

Keywords: Covid-19; Sars-CoV-2; antiviral.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST:

The authors declare no competing interests.

References

    1. Treatment. In: Kamps BS, Hoffmann C, eds. Covid Reference. Website www.covidreference.com. 2020.
    1. McCreary EK Pogue JM Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infectious Diseases. 2020;7:ofaa105–ofaa105. - PMC - PubMed
    1. Kalil AC Treating COVID-19–Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. 2020;10 - PubMed
    1. Uyeki TM Bernstein HH Bradley JS Englund JA File TM Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clinical Infectious Disesases. 2019;68 - PMC - PubMed
    1. Chan KS Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Medical Journal. 2003;9:399–406. - PubMed

MeSH terms